4 reports

  • 7.16. YESCARTA / AXICABTAGENE CILOLEUCEL / KTE-C19 (KITE PHARMA) 7.16.1. THERAPY OVERVIEW
  • Kite Pharma:

ONE OF THE FIRST CLINICAL TRIALS THAT USED THE SBTS WAS CONDUCTED IN PATIENTS SUFFERING FROM LEUKEMIA AND LYMPHOMA.

  • Immunotherapy
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Kite Pharma, Inc.
  • LIST OF TABLES
  • KEY THERAPEUTIC AREAS

POST A FOLLOW-UP OF NINE MONTHS, THREE PATIENTS REPORTED PROGRESSION AS FOLLOWS: ONE PATIENT REPORTING CR PROGRESSED ONE MONTH AFTER INFUSION WITH AGGRESSIVE CD##-NEGATIVE TRANSFORMED LYMPHOMA ##. ##. ##. ##. ##.

  • Lymphoma
  • Pharmaceutical
  • North America
  • United States
  • Kite Pharma, Inc.
  • Targets Under Clinical Studies
  • KTE-C19: CURRENT STATUS OF DEVELOPMENT

CAR-TS AND LEUKAEMIA/ LYMPHOMA TCRS AND LEUKAEMIA/ LYMPHOMA ##. ##. ##.

  • Immunotherapy
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Kite Pharma, Inc.
  • Kite Pharma Raises USD146.62 Million in IPO
  • Kite Pharma Raises USD146.62 Million in IPO

One year follow-up data from ZUMA-## study of axi-cel in patients with aggressive NHL.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Company
  • Kite Pharma, Inc.